{
  "guideline" : {
    "@id" : "https://pharmgkb.org/guidelineAnnotation/PA166178241",
    "@context" : "https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld",
    "objCls" : "Guideline Annotation",
    "id" : "PA166178241",
    "name" : "Annotation of PRO Guideline for ivacaftor and CFTR",
    "cancerGenome" : false,
    "crossReferences" : [ ],
    "descriptiveVideoId" : "",
    "guidelineGenes" : [ ],
    "history" : [ {
      "id" : 1451136801,
      "date" : "2020-05-13T00:00:00-07:00",
      "description" : "Combined all CFF guidelines into one annotation",
      "type" : "Update",
      "version" : 0
    } ],
    "literature" : [ {"@id":"https://pharmgkb.org/literature/15100546","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":15100546,"resourceId":"29342367","title":"Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.","_sameAs":"https://www.ncbi.nlm.nih.gov/pubmed/29342367","crossReferences":[{"@id":"https://pharmgkb.org/crossReference/pubMed/29342367","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449192798,"resource":"PubMed","resourceId":"29342367","_url":"https://www.ncbi.nlm.nih.gov/pubmed/29342367"},{"@id":"https://pharmgkb.org/crossReference/doi/10.1513/AnnalsATS.201707-539OT","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449192799,"resource":"DOI","resourceId":"10.1513/AnnalsATS.201707-539OT","_url":"http://dx.doi.org/10.1513%2FAnnalsATS.201707-539OT"}],"objCls":"Literature","type":"Article"}, {"@id":"https://pharmgkb.org/literature/15100545","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":15100545,"resourceId":"27009033","title":"Clinical Practice Guidelines From the Cystic Fibrosis Foundation for Preschoolers With Cystic Fibrosis.","_sameAs":"https://www.ncbi.nlm.nih.gov/pubmed/27009033","crossReferences":[{"@id":"https://pharmgkb.org/crossReference/pubMed/27009033","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449192792,"resource":"PubMed","resourceId":"27009033","_url":"https://www.ncbi.nlm.nih.gov/pubmed/27009033"},{"@id":"https://pharmgkb.org/crossReference/doi/10.1542/peds.2015-1784","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449192793,"resource":"DOI","resourceId":"10.1542/peds.2015-1784","_url":"http://dx.doi.org/10.1542%2Fpeds.2015-1784"}],"objCls":"Literature","type":"Article"}, {"@id":"https://pharmgkb.org/literature/15100544","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":15100544,"resourceId":"23540878","title":"Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health.","_sameAs":"https://www.ncbi.nlm.nih.gov/pubmed/23540878","crossReferences":[{"@id":"https://pharmgkb.org/crossReference/pubMed/23540878","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1449192789,"resource":"PubMed","resourceId":"23540878","_url":"https://www.ncbi.nlm.nih.gov/pubmed/23540878"}],"objCls":"Literature","type":"Article"} ],
    "pediatric" : false,
    "recommendation" : true,
    "relatedAlleles" : [ ],
    "relatedChemicals" : [ {
      "@id" : "https://pharmgkb.org/chemical/PA165950341",
      "@context" : "https://api.pharmgkb.org/jsonld/chemical.jsonld",
      "objCls" : "Chemical",
      "id" : "PA165950341",
      "name" : "ivacaftor",
      "version" : 5
    } ],
    "relatedGenes" : [ {
      "@id" : "https://pharmgkb.org/gene/PA109",
      "@context" : "https://api.pharmgkb.org/jsonld/gene.jsonld",
      "objCls" : "Gene",
      "id" : "PA109",
      "symbol" : "CFTR",
      "name" : "cystic fibrosis transmembrane conductance regulator",
      "version" : 18
    } ],
    "source" : "Professional Society",
    "summaryMarkdown" : {
      "id" : 1449192794,
      "html" : "<p>Ivacaftor is suggested for some cystic fibrosis patients with specific <em>CFTR</em> gating mutations, including the <a href=\"/variant/PA166157519\">R117H</a> or <a href=\"/variant/PA166157516\">G551D</a> variants.</p>\n<p>Note that the guideline also suggests that ivacaftor should not be used in patients with at least one R117H mutation who are aged under 6 years or aged 12-17 years and with ppFEV1 greater than 90% predicted.</p>\n",
      "version" : 0
    },
    "summaryVideoId" : "",
    "terms" : [ ],
    "textMarkdown" : {
      "id" : 1449192791,
      "html" : "<p>The <strong>Cystic Fibrosis Foundation</strong> (CFF) has released a number of guideines concerning the use of <a href=\"/chemical/PA165950341\">ivacaftor</a> in patients with <a href=\"/disease/PA443829\">Cystic Fibrosis</a>.</p>\n<h4 id=\"2018-guidelines\">2018 guidelines</h4>\n<p>The CFF guideline regarding transmembrane conductance regulator modulator therapy in cystic fibrosis patients contains suggestions regarding the use of ivacaftor in cystic fibrosis patients with gating mutations:</p>\n<blockquote class=\"blockquote\">\n<p>For adults and children aged 6 years and older with CF due to gating mutations other than G551D or R117H, the guideline panel made a conditional recommendation for treatment with IVA (ivacaftor).</p>\n</blockquote>\n<blockquote class=\"blockquote\">\n<p>For those with the R117H mutation, the guideline panel made a conditional recommendation for treatment with IVA for 1) adults aged 18 years or older, and 2) children aged 6–17 years with a forced expiratory volume in 1 second (FEV<sub>1</sub>) less than 90% predicted.</p>\n</blockquote>\n<blockquote class=\"blockquote\">\n<p>For those with the R117H mutation, the guideline panel made a conditional recommendation against treatment with IVA for 1) children aged 12–17 years with an FEV<sub>1</sub> greater than 90% predicted, and 2) children less than 6 years of age.</p>\n</blockquote>\n<p>excerpted from <em>Cystic Fibrosis Foundation Pulmonary Guidelines. Use of Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy in Patients with Cystic Fibrosis.</em> [Article:<a href=\"/pmid/29342367\">29342367</a>].</p>\n<p>The guideline also recommends following the 2013 CFF guideline for ivacaftor treatment in cystic fibrosis patients with at least one copy of the G551D mutation [Article:<a href=\"/pmid/23540878\">23540878</a>] and the 2016 CFF guideline for ivacaftor treatment in patients aged 2-5 years with certain <em>CFTR</em> gating mutations [Article:<a href=\"/pmid/27009033\">27009033</a>]. Excerpts from both of these guidelines are shown below.</p>\n<p>For detailed suggestions based on a patient's age and ppFEV<sub>1</sub> status, and information regarding the strength of these suggestions, please consult the guideline itself [Article:<a href=\"/pmid/29342367\">29342367</a>].</p>\n<h4 id=\"2016-guidelines-for-preschoolers\">2016 guidelines for preschoolers</h4>\n<p>The 2016 guidelines for preschoolers with cystic fibrosis include the following statement regarding the use of ivacaftor in children aged 2-5 years with a diagnosis of cystic fibrosis caused by certain <em>CFTR</em> gating mutations:</p>\n<blockquote class=\"blockquote\">\n<p>For children with CF, ages 2 through 5 y, the Preschool Guidelines Committee recommends the routine use of ivacaftor in those with specific gating mutations* and a consideration for those with a confirmed diagnosis of CF and a R117H mutation.</p>\n</blockquote>\n<blockquote class=\"blockquote\">\n<p>*The mutations are G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, and S549R.</p>\n</blockquote>\n<p>excerpted from <em>Clinical Practice Guidelines From the Cystic Fibrosis Foundation for Preschoolers With Cystic Fibrosis</em> [Article:<a href=\"/pmid/27009033\">27009033</a>]</p>\n<h4 id=\"2013-guidelines\">2013 guidelines</h4>\n<p>The 2013 guidelines from the Pulmonary Clinical Practice Guidelines Committee of the <strong>Cystic Fibrosis Foundation</strong> include the following statement regarding the use of ivacaftor in cystic fibrosis patients with at least one <em>CFTR</em> G551D mutation:</p>\n<blockquote class=\"blockquote\">\n<p>For individuals with CF, 6 years of age and older, with at least one G551D CFTR mutation, the Pulmonary Clinical Practice Guidelines Committee strongly recommends the chronic use of ivacaftor to improve lung function and quality of life and reduce exacerbations.</p>\n</blockquote>\n<p>excerpted from <em>Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health.</em> [Article:<a href=\"/pmid/23540878\">23540878</a>]</p>\n",
      "version" : 0
    },
    "userId" : "rachel",
    "version" : 0
  }
}